Subsite variation of HPV-related p16-expression in oropharynx cancer: Incidence and prognostic impact in a population-based DAHANCA cohort 1986–2020
DOI:
https://doi.org/10.2340/1651-226X.2025.44027Keywords:
Oropharyngeal cancer, HPV, subsite, TNM8 classification, radiotherapy, prognosisAbstract
p16-expression are implemented in the TNM8 classification of oropharyngeal cancer (OPSCC). Based on a nationwide cohort, we provide a detailed description of subsite variation in the age-standardised incidence-rates of OPSCC alongside an evaluation of the prognostic impact of p16-expression according to subsite after primary radiotherapy (RT).
Patient/material and methods: A total of 8,462 Danish OPSCC patients from 1986 to 2020 were identified in the DAHANCA-database, and tumours were grouped into ‘tonsil/base of tongue (BOT)’, ‘neighbouring subsites’ and ‘distant subsites’. Subsite-specific age-standardised incidence-rates were calculated, and outcome-analysis (loco-regional control, disease-free survival and overall-survival 5 years after the completion of RT) stratified by p16-status/subsite and restricted to curatively treated patients only (N = 3,387) was performed.
Results: A 5-fold increase in the age-standardised incidence of OPSCC was observed and could be ascribed to the rise in p16-positive tumours of tonsil/BOT and neighbouring subsites only as neither the incidence rates nor the proportion of p16-positivity in distant subsites tumours changed over time. The prognostic impact of p16-status for all endpoints differed significantly across tumour subsites with the strongest association found in tonsil/BOT tumours, a diminishing but still significant impact in neighbouring subsite tumours and no significant impact in tumours arising in distant subsites.
Interpretation: Our findings suggest that grouping all p16-positive OPSCC as one entity for staging and prognostication, as currently done in TNM8, is too simple as it does not accurately depict the differences in tumour biology and the consequent treatment response.
Downloads
References
Decker J, Goldstein JC. Risk factors in head and neck cancer. N Engl J Med. 1982;306:1151–5.
https://doi.org/10.1056/NEJM198205133061905 DOI: https://doi.org/10.1056/NEJM198205133061905
Gillison ML. Evidence for a causal association between human papillomavirus and a subset of head and neck cancers. J Natl Cancer Inst. 2000;92(9):709–20.
https://doi.org/10.1093/jnci/92.9.709 DOI: https://doi.org/10.1093/jnci/92.9.709
D’Souza G, Kreimer AR, Viscidi R, Pawlita M, Fakhry C, Koch WM, et al. Case–control study of human papillomavirus and oropharyngeal cancer. N Engl J Med. 2007;356(19):1944–56.
https://doi.org/10.1056/NEJMoa065497 DOI: https://doi.org/10.1056/NEJMoa065497
Kreimer AR, Clifford GM, Boyle P, Franceschi S. Human papillomavirus types in head and neck squamous cell carcinomas worldwide: a systemic review. Cancer Epidemiol Biomarkers Prev. 2005;14(2):467–75.
https://doi.org/10.1158/1055-9965.EPI-04-0551 DOI: https://doi.org/10.1158/1055-9965.EPI-04-0551
Isayeva T, Li Y, Maswahu D, Brandwein-Gensler M. Human papillomavirus in non-oropharyngeal head and neck cancers: a systematic literature review. Head Neck Pathol. 2012;6:104–20.
https://doi.org/10.1007/s12105-012-0368-1 DOI: https://doi.org/10.1007/s12105-012-0368-1
Ndiaye C, Mena M, Alemany L, Arbyn M, Castellsagué X, Laporte L, et al. HPV DNA, E6/E7 mRNA, and p16INK4a detection in head and neck cancers: a systematic review and meta-analysis. Lancet Oncol. 2014;15(12):1319–31. DOI: https://doi.org/10.1016/S1470-2045(14)70471-1
Mariz Bala, Kowalski LP, William WN, de Castro G, Chaves ALF, Santos M, et al. Global prevalence of human papillomavirus-driven oropharyngeal squamous cell carcinoma following the ASCO guidelines: a systematic review and meta-analysis. Crit Rev Oncol Hematol. 2020;156:103–16.
https://doi.org/10.1016/j.critrevonc.2020.103116 DOI: https://doi.org/10.1016/j.critrevonc.2020.103116
Lassen P, Eriksen JG, Hamilton-Dutoit S, Tramm T, Alsner J, Overgaard J.
Effect of HPV-associated p16INK4A expression on response to radiotherapy and survival in squamous cell carcinoma of the head and neck. J Clin Oncol. 2009;27(12):1992–8.
https://doi.org/10.1200/JCO.2008.20.2853 DOI: https://doi.org/10.1200/JCO.2008.20.2853
Lassen P, Eriksen JG, Hamilton-Dutoit S, Tramm T, Alsner J, Overgaard J.
HPV-associated p16-expression and response to hypoxic modification of radiotherapy in head and neck cancer. Radiother Oncol. 2010;94(1):30–5.
https://doi.org/10.1016/j.radonc.2009.10.008 DOI: https://doi.org/10.1016/j.radonc.2009.10.008
Lassen P, Eriksen JG, Krogdahl A, Therkildsen MH, Ulhøi BP, Overgaard M, et al. The influence of HPV-associated p16-expression on accelerated fractionated radiotherapy in head and neck cancer: evaluation of the randomised DAHANCA 6&7 trial. Radiother Oncol. 2011;100(1):49–55.
https://doi.org/10.1016/j.radonc.2011.02.010 DOI: https://doi.org/10.1016/j.radonc.2011.02.010
Fakhry C, Westra WH, Li S, Cmelak A, Ridge JA, Pinto H, et al. Improved survival of patients with human papillomavirus–positive head and neck squamous cell carcinoma in a prospective clinical trial. J Natl Cancer Inst. 2008;100(4):261–9.
https://doi.org/10.1093/jnci/djn011 DOI: https://doi.org/10.1093/jnci/djn011
Lassen P, Primdahl H, Johansen J, Kristensen CA, Andersen E, Andersen LJ, et al. Impact of HPV-associated p16-expression on radiotherapy outcome in advanced oropharynx and non-oropharynx cancer. Radiother Oncol. 2014;113(3):310–6.
10.1016/j.radonc.2014.11.032 DOI: https://doi.org/10.1016/j.radonc.2014.11.032
Ang KK, Harris J, Wheeler R, Weber R, Rosenthal DI, Nguyen-Tân PF, et al. Human papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med. 2010;363:24–35.
https://doi.org/10.1056/NEJMoa0912217 DOI: https://doi.org/10.1056/NEJMoa0912217
Lassen P, Huang SH, Su J, Waldron J, Andersen M, Primdahl P, et al. Treatment outcomes and survival following definitive (chemo)radiotherapy in HPV-positive oropharynx cancer: large-scale comparison of DAHANCA vs PMH cohorts. Int J Cancer. 2022;150:1329–40.
https://doi.org/10.1002/ijc.33876 DOI: https://doi.org/10.1002/ijc.33876
O’Sullivan B, Huang SH, Su J, Garden AS, Sturgis EM, Dahlstrom K,
et al. Development and validation of a staging system for HPV-related oropharyngeal cancer by the International Collaboration on Oropharyngeal Cancer Network for Staging (ICON-S): a multicentre cohort study. Lancet Oncol. 2016;17(4):440–51.
10.1016/S1470-2045(15)00560-4 DOI: https://doi.org/10.1016/S1470-2045(15)00560-4
Mehanna H, Taberna M, von Buchwald C, Tous S, Brooks J, Mena M, et al. HNCIG-EPIC group. Prognostic implications of p16 and HPV discordance in oropharyngeal cancer (HNCIG-EPIC-OPC): a multicentre, multinational, individual patient data analysis. Lancet Oncol. 2023;24:239–51.
https://doi.org/10.1016/S1470-2045(23)00013-X DOI: https://doi.org/10.1016/S1470-2045(23)00013-X
Marklund L, Holzhauser S, de Flon C, Zupancic M, Landin D, Kolev A,
et al. Survival of patients with oropharyngeal squamous cell carcinomas (OPSCC) in relation to TNM 8 Risk of incorrect downstaging of HPV-mediated non-tonsillar, non-base of tongue carcinomas. Eur J Cancer. 2020;139:192–200. DOI: https://doi.org/10.1016/j.ejca.2020.08.003
j.ejca.2020.08.003 DOI: https://doi.org/10.1088/1475-7516/2020/08/003
Overgaard J, Jovanovic A, Godballe C, Eriksen JG. The Danish Head and Neck Cancer database. Clin Epidemiol. 2016;8:491–6.
10.2147/CLEP.S103591 DOI: https://doi.org/10.2147/CLEP.S103591
Jensen K, Friborg J, Hansen CR, Samsøe E, Johansen J, Andersen M, et al. The Danish Head and Neck Cancer Group (DAHANCA) 2020 radiotherapy guidelines. Radiother Oncol. 2020;151:149–51.
https://doi.org/10.1016/j.radonc.2020.07.037 DOI: https://doi.org/10.1016/j.radonc.2020.07.037
Lassen P, Overgaard J. Scoring and classification of oropharyngeal carcinoma based on HPV-related p16-expression. Radiother Oncol. 2012;105:269–70.
https://doi.org/10.1016/j.radonc.2012.09.017 DOI: https://doi.org/10.1016/j.radonc.2012.09.017
Fakhry C, Lacchetti C, Rooper LM, Jordan RC, Rischin D, Sturgis EM, et al. Human papillomavirus testing in head and neck carcinomas: ASCO Clinical Practice Guideline Endorsement of the College of American Pathologists Guideline. J Clin Oncol. 2018;36:3152–61.
https://doi.org/10.1200/JCO.18.00684 DOI: https://doi.org/10.1200/JCO.18.00684
Hoff CM, Grau C, Overgaard J. Effect of smoking on oxygen delivery and outcome in patients treated with radiotherapy for head and neck squamous cell carcinoma: a prospective study. Radiother Oncol. 2012;103(1):38–44.
https://doi.org/10.1016/j.radonc.2012.01.011 DOI: https://doi.org/10.1016/j.radonc.2012.01.011
Baumann M, Krause M, Overgaard J, Debus J, Bentzen SM, Daartz J, et al. Radiation oncology in the era of precision medicine. Nat Rev Cancer. 2016;16(4):234–49.
https://doi.org/10.1038/nrc.2016.18 DOI: https://doi.org/10.1038/nrc.2016.18
Albers AE, Qian X, Kaufmann AM, Coordes A. Meta analysis: HPV and p16 pattern determines survival in patients with HNSCC and identifies potential new biologic subtype. Sci Rep. 2017;7(1):16715.
https://doi.org/10.1038/s41598-017-16918-w DOI: https://doi.org/10.1038/s41598-017-16918-w
Additional Files
Published
How to Cite
Issue
Section
Categories
License
Copyright (c) 2025 Pernille Lassen, Jan Alsner, Hanne Primdahl, Christina Caroline Plaschke, Christian Maare, Jørgen Johansen, Maria Andersen, Mohammad Farhadi, Jens Overgaard
This work is licensed under a Creative Commons Attribution 4.0 International License.
